Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Shi, J., Li, Y., Jia, R
In laboratory testing, it did not inhibit related SAM-dependent methyltransferases or interfere with other enzymes in NAD+ salvage pathways
BPC-157 is a kind of chemical called a peptide, and the Food and Drug Administration treats it and some other peptides as unapproved drugs going so far in 2023 as to explicitly prohibit compounding pharmacies from supplying BPC-157 to patients
Fiorillo et al., 2022
Compounding BPC-157: A regulatory loophole In a statement, Health Canada said "BPC157 has not been authorized, its safety, efficacy, and quality have not been assessed and there is limited scientific evidence to support its use, including a lack of established human dosing protocols." In addition, the regulator says BPC-157 is not approved for use in any NHPs in any form, including oral and injectable, but it can still be compounded for topical use or oral administration as an NHP
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
